These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25217182)

  • 1. New chapter unfolding in the fight against dengue with an unwritten ending.
    Thiry G; Hombach J; Constenla D; Carvalho A; Durbin A
    Trans R Soc Trop Med Hyg; 2014 Oct; 108(10):597-8. PubMed ID: 25217182
    [No Abstract]   [Full Text] [Related]  

  • 2. Dengue vaccines for travelers: has the time come?
    Wilder-Smith A
    J Travel Med; 2015; 22(3):200-2. PubMed ID: 25827475
    [No Abstract]   [Full Text] [Related]  

  • 3. Defeating dengue: a challenge for a vaccine.
    Nat Med; 2012 Nov; 18(11):1622-3. PubMed ID: 23135514
    [No Abstract]   [Full Text] [Related]  

  • 4. The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection.
    Pitisuttithum P; Bouckenooghe A
    Expert Rev Vaccines; 2016 Jul; 15(7):795-8. PubMed ID: 27171845
    [No Abstract]   [Full Text] [Related]  

  • 5. Sanofi's dengue vaccine first to complete phase 3.
    Sinha G
    Nat Biotechnol; 2014 Jul; 32(7):605-6. PubMed ID: 25004214
    [No Abstract]   [Full Text] [Related]  

  • 6. Dengue vaccine candidates in development.
    Durbin AP; Whitehead SS
    Curr Top Microbiol Immunol; 2010; 338():129-43. PubMed ID: 19802583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the role of a recently licensed dengue vaccine in Australian travellers.
    Thevarajan I; Torresi J; Simmons C
    Med J Aust; 2020 Feb; 212(3):102-103.e1. PubMed ID: 31909484
    [No Abstract]   [Full Text] [Related]  

  • 8. Serostatus-dependent performance of the first licensed dengue vaccine: implications for travellers.
    Wilder-Smith A
    J Travel Med; 2018 Aug; 25(1):. PubMed ID: 30016457
    [No Abstract]   [Full Text] [Related]  

  • 9. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
    Simmons M; Burgess T; Lynch J; Putnak R
    Virology; 2010 Jan; 396(2):280-8. PubMed ID: 19913867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A recombinant live attenuated tetravalent vaccine for the prevention of dengue.
    Guy B; Noriega F; Ochiai RL; L'azou M; Delore V; Skipetrova A; Verdier F; Coudeville L; Savarino S; Jackson N
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28590795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate.
    Gessner BD; Wilder-Smith A
    Vaccine; 2016 Apr; 34(20):2397-401. PubMed ID: 27055020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targets and strategies for vaccine development against dengue viruses.
    Wang WH; Urbina AN; Lin CY; Yang ZS; Assavalapsakul W; Thitithanyanont A; Lu PL; Chen YH; Wang SF
    Biomed Pharmacother; 2021 Dec; 144():112304. PubMed ID: 34634560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should travellers be offered vaccination against the dengue virus?
    Javelle E; Al Balushi A; Jespersen S; Al Abri S; Gautret P; Petersen E
    Travel Med Infect Dis; 2019; 27():2-4. PubMed ID: 30267771
    [No Abstract]   [Full Text] [Related]  

  • 14. [Analysis of the evidence on the efficacy and safety of CYD-TDV dengue vaccine and its potential licensing and implementation through Mexico's Universal Vaccination Program].
    Hernández-Ávila M; Lazcano-Ponce E; Hernández-Ávila JE; Alpuche-Aranda CM; Rodríguez-López MH; García-García L; Madrid-Marina V; López Gatell-Ramírez H; Lanz-Mendoza H; Martínez-Barnetche J; Díaz-Ortega JL; Ángeles-Llerenas A; Barrientos-Gutiérrez T; Bautista-Arredondo S; Santos-Preciado JI
    Salud Publica Mex; 2016; 58(1):71-83. PubMed ID: 26879510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Status of vaccine research and development of vaccines for dengue.
    Vannice KS; Durbin A; Hombach J
    Vaccine; 2016 Jun; 34(26):2934-2938. PubMed ID: 26973072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dengue vaccines approach the finish line.
    Edelman R
    Clin Infect Dis; 2007 Jul; 45 Suppl 1():S56-60. PubMed ID: 17582571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The human dengue challenge experience at the Walter Reed Army Institute of Research.
    Lyons AG
    J Infect Dis; 2014 Jun; 209 Suppl 2():S49-55. PubMed ID: 24872396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico.
    Bauer K; Esquilin IO; Cornier AS; Thomas SJ; Quintero Del Rio AI; Bertran-Pasarell J; Morales Ramirez JO; Diaz C; Carlo S; Eckels KH; Tournay E; Toussaint JF; De La Barrera R; Fernandez S; Lyons A; Sun W; Innis BL
    Am J Trop Med Hyg; 2015 Sep; 93(3):441-453. PubMed ID: 26175027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SAGE committee advice on dengue vaccine.
    Pang T
    Lancet Infect Dis; 2016 Aug; 16(8):880-2. PubMed ID: 27477966
    [No Abstract]   [Full Text] [Related]  

  • 20. Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines.
    Russell PK; Halstead SB
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004854. PubMed ID: 27513928
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.